Literature DB >> 19363519

Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases.

Sen-sen Lin1, Li Sun, Yan-kai Zhang, Ren-ping Zhao, Wen-lu Liang, Sheng-tao Yuan, Lu-yong Zhang.   

Abstract

AIM: The aim of this study was to investigate the effect of topotecan (TPT) on cancer cell migration.
METHODS: Growth inhibition of TPT was analyzed by MTT assay, and cancer cell migration was measured by transwell double chamber assay. To verify the effect of TPT on the chemokine receptors CXCR4 and CCR7, quantitative PCR, semi-quantitative PCR and Western blot analysis were performed. The secretion of MMP-2 and MMP-9 was detected by enzyme-linked immunosorbent assay (ELISA) and gelatin zymography. To evaluate possible contributions of CCR7 to MMP secretion, the overexpression vectors pcDNA3.1(+)-CCR7 and CCR7 siRNA were transiently transfected into MDA-MB-435 cells.
RESULTS: TPT inhibited cancer cell migration in a dose-dependent manner. Additionally, TPT significantly decreased the expression of CCR7 in both MDA-MB-435 and MDA-MB-231 cells and moderately reduced the expression of CXCR4 in MDA-MB-435 cells. The secretion of MMPs (MMP-2, MMP-9) was also inhibited by TPT. Overexpression of CCR7 increased the secretion of MMP-2/9 and cancer cell migration, whereas knockdown of CCR7 reduced active MMP-2/9 production and migration of MDA-MB-435 cells.
CONCLUSION: TPT inhibited cancer cell migration by down-regulation of CCR7 and MMPs (MMP-2 and MMP-9).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19363519      PMCID: PMC4002819          DOI: 10.1038/aps.2009.32

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  32 in total

1.  Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.

Authors:  J von Pawel; U Gatzemeier; J L Pujol; L Moreau; S Bildat; M Ranson; G Richardson; C Steppert; A Rivière; I Camlett; S Lane; G Ross
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

2.  Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study.

Authors:  C Oberhoff; D G Kieback; R Würstlein; H Deertz; J Sehouli; C van Soest; J Hilfrich; M Mesrogli; G von Minckwitz; H J Staab; A E Schindler
Journal:  Onkologie       Date:  2001-06

Review 3.  Chemokines in cancer.

Authors:  Alain P Vicari; Christophe Caux
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

4.  Invasiveness corresponds to differentiation rather than to proteinase secretion in endometrial cancer cell lines.

Authors:  M Sillem; S Prifti; A Koumouridis; B Runnebaum
Journal:  Eur J Gynaecol Oncol       Date:  1999       Impact factor: 0.196

5.  Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.

Authors:  M Rodriguez; P G Rose
Journal:  Gynecol Oncol       Date:  2001-11       Impact factor: 5.482

6.  Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study.

Authors:  A Korfel; C Oehm; J von Pawel; Uwe Keppler; M Deppermann; S Kaubitsch; E Thiel
Journal:  Eur J Cancer       Date:  2002-09       Impact factor: 9.162

7.  CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells.

Authors:  Weidong Hu; Xinming Zhen; Bin Xiong; Bicheng Wang; Weibing Zhang; Wenhui Zhou
Journal:  Cancer Sci       Date:  2008-04-29       Impact factor: 6.716

8.  CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells.

Authors:  Hiroya Takeuchi; Akihide Fujimoto; Maki Tanaka; Tomoki Yamano; Eddy Hsueh; Dave S B Hoon
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

9.  Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.

Authors:  Zhongxing Liang; Tao Wu; Hong Lou; Xiwen Yu; Russell S Taichman; Stephen K Lau; Shuming Nie; Jay Umbreit; Hyunsuk Shim
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

Review 10.  Dissemination and growth of cancer cells in metastatic sites.

Authors:  Ann F Chambers; Alan C Groom; Ian C MacDonald
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

View more
  3 in total

1.  Interstitial flow influences direction of tumor cell migration through competing mechanisms.

Authors:  William J Polacheck; Joseph L Charest; Roger D Kamm
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

2.  The selective anti-proliferative and pro-apoptotic effect of A. cherimola on MDA-MB-231 breast cancer cell line.

Authors:  Maria Younes; Carl Ammoury; Tony Haykal; Leah Nasr; Rita Sarkis; Sandra Rizk
Journal:  BMC Complement Med Ther       Date:  2020-11-13

3.  Paclitaxel treatment enhances lymphatic metastasis of B16F10 melanoma cells via CCL21/CCR7 axis.

Authors:  Li Zhang; Linyu Zhu; Xiaohan Yao; Xiaohan Lou; Jiajia Wan; Xixi Duan; Longze Pan; Anqi Li; Zhuoyu Gu; Ming Wang; Fazhan Wang; Zhihai Qin
Journal:  Int J Biol Sci       Date:  2022-01-24       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.